Login
$SMMT
$11.90 +$0.08 (0.68%) After hours

$SMMT 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Other Events

Date of Report (Date of Earliest Event Reported): November 15, 2026

04 Nov 2026 8-K: Other Events

We have acted as counsel to Summit Therapeutics Inc., a Delaware corporation (the “Company”), in connection with the Registration Statement on Form S-3 (File No. 333- 296642) (the “Registration Statement”) filed by the Company with the S...

04 Nov 2026 8-K: Results of Operations and Financial Condition; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

1 Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 Recent $2 Billion Strategic Equity Investment in Summit by AstraZeneca and Summit’s Expanding Network...

29 Sep 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of September 28, 2026, by and between Summit Therapeutics Inc., a Delaware corporation (the “Company”), and AstraZeneca Holdings B.V., a Dutch private limited liability co...

15 Sep 2026 8-K: Other Events

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients Sustained OS Improvement Seen with Longer Follow-Up in Western Patients, Consist...

14 Sep 2026 8-K: Other Events

1 Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China Ivonescimab Reduced t...

03 Sep 2026 8-K: Other Events

1 Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China Summit is Conducting HARMONi-...

26 Aug 2026 8-K: Other Events

1 Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China HARMO...

05 Aug 2026 8-K: Other Events

1 Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer HARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Cancer...

23 Jul 2026 8-K: Entry into a Material Definitive Agreement

Summit Therapeutics Inc., a Delaware corporation (the “Company”), confirms its agreement with J.P. Morgan Securities LLC, as agent and/or principal under any Terms Agreement (as defined in Section 1(a) below) (“you” or the “Agent”), with...

23 Jul 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi S...

22 Jul 2026 8-K: Other Events

Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study Western Patients Achieved OS HR of 0.76, Consistent with Asian Patie...

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 10, 2026, Summit Therapeutics Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The following matters were submitted to a vote of the Company’s stockholders at the Annual Meeting: (i) the e...

11 Jun 2026 8-K: Regulation FD Disclosure

Summit Therapeutics Inc. (the “Company”) announced that effective June 10, 2026 it has withdrawn its previously announced proposed underwritten public offering of securities due to market conditions.

03 Jun 2026 8-K: Other Events

On June 2, 2026, the Audit Committee and all independent directors of the Board of Directors of Summit Therapeutics Inc. (the “Company”) approved one or more Company affiliates to purchase shares of the Company’s common stock under the p...

01 Jun 2026 8-K: Other Events

Summit Therapeutics ASCO 2026 Update Call June 1, 2026 7:00am ET

30 Apr 2026 8-K: Results of Operations and Financial Condition

1 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 Overall Survival Data to be Featured at ASCO 2026 Plenary Session as Late-Breaking Abstract from HARMONi-6, a Phase III S...

23 Feb 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

1 Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final...

29 Jan 2026 8-K: Other Events

1 Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy BLA Filing Based on H...

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

44th Annual J.P. Morgan Healthcare Conference January 12, 2026 BOB DUGGAN Chairman & Co-Chief Executive Officer DR. MAKY ZANGANEH President & Co-Chief Executive Officer

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support